Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Takes Another Step On Planned Generic Exit

Divestiture Takes It Closer To Being A Consumer-Focused Self-Care Firm

Executive Summary

Perrigo’s ambitions to become a consumer-focused company are a step closer after the firm announced an immediate sale of a ‘non-core’ asset.

You may also be interested in...



‘Fast Forward Four Or Five Years, We’re Going To Look Very Different’ – Rosemont Chief Eyes ‘Transformative’ International M&A

UK-based liquids specialist Rosemont Pharmaceuticals is on the lookout for M&A opportunities, particularly as it looks to build up its business in the US, chief executive Howard Taylor tells Generics Bulletin in an exclusive interview.

Who’s Hired? Rosemont Drives M&A With New Appointments

UK liquids specialist Rosemont Pharmaceuticals has appointed a new chief corporate development officer to drive M&A. Meanwhile, EuroAPI has named a chief transformation officer, Zentiva’s CEO has joined Medicines for Europe’s executive committee, Hikma has changed company secretary, and Xbrane has made alterations to its nominations committee.

Juno Deal Gives Rosemont Access To Canada

Juno Pharmaceuticals has struck a deal that will see it act as the exclusive distributor for UK-based Rosemont’s oral liquid medicines in Canada.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB150007

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel